Advanced in Embryonal Tumor with Multilayered Rosettes

Dr. Leo Mascarenhas

Pediatric Hematology Oncology

Cedars Sinai

Cedars-Sinai Medical Center

8700 Beverly Blvd,

West Hollywood, CA

Clinical Trials:Currently Recruiting for 7 Trials

Advanced in Embryonal Tumor with Multilayered Rosettes

Cedars Sinai

Cedars-Sinai Medical Center

8700 Beverly Blvd,

West Hollywood, CA

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Leo Mascarenhas is a Pediatric Hematologist Oncology provider in West Hollywood, California. Dr. Mascarenhas is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Rhabdomyosarcoma, Adult Soft Tissue Sarcoma, Osteosarcoma, Bone Marrow Aspiration, and Tissue Biopsy.

His clinical research consists of co-authoring 102 peer reviewed articles and participating in 90 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 23 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatric Hematology-Oncology in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem

Blue Shield of California

HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE-MEDICAID PLAN
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D
PPO

Cigna

Medicaid

OTHER MEDICAID
STATE MEDICAID

Optima Health

Oscar

Trustmark

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 4 Less Insurance Carriers -

Locations

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Blvd, West Hollywood, CA 90048

Call: 310-423-3277

Additional Areas of Focus

Dr. Mascarenhas has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

89 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Enrollment Status: Recruiting

Publish Date: October 10, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Busulfan, Carboplatin, Cisplatin, Crizotinib, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Isotretinoin, Melphalan Hydrochloride, Sargramostim, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Procedure, Other, Drug

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Dexrazoxane, Etoposide, Gemtuzumab, Gilteritinib, Liposomal Daunorubicin, Liposomal Cytarabine, Methotrexate, Mitoxantrone, Hydrocortisone

Study Phase: Phase 3

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Procedure, Drug, Biological, Radiation, Other

Study Drugs: Calaspargase, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Inotuzumab, Leucovorin, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Thioguanine, Vincristine

Study Phase: Phase 3

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Enrollment Status: Recruiting

Publish Date: September 18, 2025

Intervention Type: Drug, Procedure, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Inotuzumab, Leucovorin, 6-Mercaptopurine, Pegaspargase, Vincristine

Study Phase: Phase 2

A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse

Enrollment Status: Recruiting

Publish Date: September 10, 2025

Intervention Type: Procedure, Drug, Radiation, Biological

Study Drugs: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nivolumab, Pegaspargase, Thioguanine, Vincristine Sulfate

Study Phase: Phase 2

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Enrollment Status: Recruiting

Publish Date: August 12, 2025

Intervention Type: Other

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

Enrollment Status: Recruiting

Publish Date: February 14, 2025

Intervention Type: Drug

Study Drug: Oral Repotrectinib (TPX-0005)

Study Phase: Phase 1/Phase 2

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2025

Intervention Type: Drug, Biological, Procedure, Other, Radiation

Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine

Study Phase: Phase 3

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Enrollment Status: Active_not_recruiting

Publish Date: October 15, 2025

Intervention Type: Drug, Procedure, Biological, Other, Radiation

Study Drugs: Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: October 09, 2025

Intervention Type: Drug, Biological, Procedure, Radiation

Study Drugs: Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine

Study Phase: Phase 2

A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Radiation

Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Drug, Procedure, Biological, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Ganitumab, Ifosfamide, Vincristine, Vincristine Sulfate

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Ensartinib in Patients With Tumors Harboring ALK or ROS1 Genomic Alterations

Enrollment Status: Active_not_recruiting

Publish Date: October 07, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Ensartinib

Study Phase: Phase 2

The Effectiveness of Lactobacillus Plantarum (LBP, IND# 17339) in Preventing Acute Graft-Versus-Host Disease (GvHD) in Children Undergoing Alternative Hematopoietic Progenitor Cell Transplantation (HCT)

Enrollment Status: Active_not_recruiting

Publish Date: October 06, 2025

Intervention Type: Procedure, Other, Biological

Study Drugs: Lactobacillus Plantarum Strain 299, Lactobacillus Plantarum Strain 299v

Study Phase: Phase 3

Phase II Study of Nab-Paclitaxel in Combination With Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults

Enrollment Status: Active_not_recruiting

Publish Date: October 01, 2025

Intervention Type: Drug

Study Drugs: Nab-Paclitaxel, Gemcitabine

Study Phase: Phase 2

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Enrollment Status: Active_not_recruiting

Publish Date: September 23, 2025

Intervention Type: Biological, Drug, Procedure, Radiation

Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate

Study Phase: Phase 3

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Radiation, Drug, Biological, Other

Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine

Study Phase: Phase 3

A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Enrollment Status: Active_not_recruiting

Publish Date: September 22, 2025

Intervention Type: Drug, Behavioral, Other, Procedure

Study Drug: 6-Mercaptopurine

Study Phase: Phase 3

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Erdafitinib in Patients With Tumors Harboring FGFR1/2/3/4 Alterations

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Procedure, Other, Drug

Study Drug: Erdafitinib

Study Phase: Phase 2

International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Procedure, Other, Biological

Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults With Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors

Enrollment Status: Active_not_recruiting

Publish Date: September 19, 2025

Intervention Type: Drug, Other

Study Drugs: Cabozantinib, Cabozantinib-S-Malate

Study Phase: Phase 2

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Other, Procedure

A Phase II Trial of Avelumab, A Fully Human Antibody That Targets Cells Expressing PD-L1, in Patients With Recurrent or Progressive Osteosarcoma

Enrollment Status: Completed

Publish Date: September 04, 2025

Intervention Type: Other, Drug

Study Drug: Avelumab

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Enrollment Status: Active_not_recruiting

Publish Date: September 03, 2025

Intervention Type: Procedure, Drug, Other

Study Drugs: Ensartinib, Erdafitinib, Larotrectinib, Olaparib, Palbociclib, Samotolisib, Selpercatinib, Selumetinib Sulfate, Tazemetostat, Tipifarnib, Ulixertinib, Vemurafenib

Study Phase: Phase 2

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Enrollment Status: Active_not_recruiting

Publish Date: September 02, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate

Study Phase: Phase 3

A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2025

Intervention Type: Drug, Other, Radiation

Study Drugs: Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: August 21, 2025

Intervention Type: Drug, Biological, Radiation

Study Drugs: Erwinia Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy With Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) Plus VINO-CPO Maintenance in Patients With High Risk Rhabdomyosarcoma (HR-RMS)

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Procedure, Drug, Biological, Radiation

Study Drug: Cyclophosphamide

Study Phase: Phase 3

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Radiation, Other

Study Drugs: Cisplatin, Cyclophosphamide, Lomustine, Vincristine, Vincristine Sulfate

Study Phase: Phase 2

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Tyrosine Kinase Inhibitor

Study Phase: Phase 2

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: August 12, 2025

Intervention Type: Drug, Procedure, Other

Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide

Study Phase: Phase 3

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754)

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Drug, Radiation, Procedure

Study Drugs: Doxorubicin, Ifosfamide, Pazopanib

Study Phase: Phase 2/Phase 3

A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Other, Drug

Study Drugs: Asparaginase, Bortezomib, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Sorafenib

Study Phase: Phase 3

Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment

Enrollment Status: Active_not_recruiting

Publish Date: August 11, 2025

Intervention Type: Drug, Other, Procedure

Study Drugs: Cisplatin, Dexrazoxane, Doxorubicin Hydrochloride, Fluorouracil, Irinotecan Hydrochloride, Temsirolimus, Vincristine Sulfate

Study Phase: Phase 3

A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination With Azacitidine in Patients With Recurrent, Resectable Osteosarcoma

Enrollment Status: Active_not_recruiting

Publish Date: August 05, 2025

Intervention Type: Drug, Procedure

Study Drugs: Nivolumab, Azacitidine

Study Phase: Phase 1

Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome

Enrollment Status: Active_not_recruiting

Publish Date: August 01, 2025

Intervention Type: Drug, Other

Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine

Study Phase: Phase 3

A Safety, Pharmacokinetic and Efficacy Study of a y-Secretase Inhibitor, Nirogacestat (PF-03084014), in Children and Adolescents With Progressive, Surgically Unresectable Desmoid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Procedure, Drug

Study Drug: Nirogacestat

Study Phase: Phase 2

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults

Enrollment Status: Active_not_recruiting

Publish Date: July 28, 2025

Intervention Type: Other, Drug, Biological

Study Drugs: Bleomycin, Brentuximab, Cyclophosphamide, Doxorubicin, Etoposide, Methylprednisolone, Prednisone, Vincristine

Study Phase: Phase 3

A Randomized, Open-Label Phase 1/2 Study Evaluating Ramucirumab in Pediatric Patients and Young Adults With Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor

Enrollment Status: Active_not_recruiting

Publish Date: July 20, 2025

Intervention Type: Drug

Study Drugs: Ramucirumab, Cyclophosphamide, Vinorelbine

Study Phase: Phase 1/Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions

Enrollment Status: Active_not_recruiting

Publish Date: July 09, 2025

Intervention Type: Procedure, Drug

Study Drugs: Larotrectinib, Larotrectinib Sulfate

Study Phase: Phase 2

A Phase 1/2 Study of the Oral TRK Inhibitor Larotrectinib in Pediatric Patients With Advanced Solid or Primary Central Nervous System Tumors

Enrollment Status: Active_not_recruiting

Publish Date: June 22, 2025

Intervention Type: Drug

Study Drug: Larotrectinib (Vitravki, BAY2757556)

Study Phase: Phase 1/Phase 2

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin Administered as a 1-Hour Infusion in Ewing Sarcoma Patients in Combination With Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

Enrollment Status: Completed

Publish Date: April 29, 2025

Intervention Type: Other, Drug, Diagnostic test

Study Drugs: Trabectedin, Irinotecan

Study Phase: Phase 1/Phase 2

Pharmacologic Reversal of Ventricular Remodeling in Childhood Cancer Survivors at Risk for Heart Failure (PREVENT-HF): A Phase 2b Randomized Placebo-Controlled (Carvedilol) Trial

Enrollment Status: Completed

Publish Date: April 23, 2025

Intervention Type: Other, Drug

Study Drug: Carvedilol

Study Phase: Phase 2

A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Enrollment Status: Active_not_recruiting

Publish Date: April 23, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 1/Phase 2

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab With or Without Eflornithine (DFMO) in Children With Relapsed, Refractory or Progressive Neuroblastoma

Enrollment Status: Active_not_recruiting

Publish Date: April 09, 2025

Intervention Type: Drug, Biological

Study Drugs: Dinutuximab, Eflornithine Hydrochloride, Irinotecan Hydrochloride, Sargramostim, Temozolomide

Study Phase: Phase 2

Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)

Enrollment Status: Active_not_recruiting

Publish Date: April 01, 2025

Intervention Type: Other, Drug

Study Drugs: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine Sulfate

Study Phase: Phase 3

Renal Tumors Classification, Biology, and Banking Study

Enrollment Status: Active_not_recruiting

Publish Date: March 25, 2025

Intervention Type: Other

Key Adverse Events After Childhood Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 07, 2025

Intervention Type: Other

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement

Enrollment Status: Completed

Publish Date: February 27, 2025

Intervention Type: Procedure, Drug

Study Drugs: Azacitidine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Hydrocortisone, Leucovorin, Mercaptopurine, Methotrexate, PEG-Asparaginase, Prednisolone, Thioguanine, Vincristine

Study Phase: Phase 2

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations

Enrollment Status: Completed

Publish Date: February 05, 2025

Intervention Type: Drug, Other

Study Drugs: Selumetinib, Selumetinib Sulfate

Study Phase: Phase 2

View 43 Less Clinical Trials

102 Total Publications

Current Approaches to the Treatment of Pediatric Soft Tissue Sarcomas: Rhabdomyosarcoma and Nonrhabdomyosarcoma Soft Tissue Sarcomas.

Journal: Hematology/oncology clinics of North America

Published: May 15, 2025

View All 102 Publications

Similar Doctors

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Shahab Asgharzadeh

Pediatric Hematology Oncology

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Shahab Asgharzadeh

Pediatric Hematology Oncology

4650 W Sunset Blvd, Ms# 54,

Los Angeles, CA

(5.4 miles away)

323-361-4151

Languages Spoken:

English

See accepted insurances

Shahab Asgharzadeh is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Asgharzadeh is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Embryonal Tumor with Multilayered Rosettes, Neuroblastoma, Medulloblastoma, and Glioma.

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Araz Marachelian

Pediatric Hematology Oncology

Elite in Embryonal Tumor with Multilayered Rosettes

Dr. Araz Marachelian

Pediatric Hematology Oncology

Childrens Hospital Los Angeles Medical Group Inc

4650 W Sunset Blvd,

Los Angeles, CA

(5.4 miles away)

323-361-8408

Languages Spoken:

English

See accepted insurances

Araz Marachelian is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Marachelian is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Hereditary Neuroblastoma, and Infantile Neutropenia.

Distinguished in Embryonal Tumor with Multilayered Rosettes

Dr. Judith G. Villablanca

Pediatric Hematology Oncology

Distinguished in Embryonal Tumor with Multilayered Rosettes

Dr. Judith G. Villablanca

Pediatric Hematology Oncology

4650 W Sunset Blvd,

Los Angeles, CA

(5.4 miles away)

323-669-2121

Languages Spoken:

English

Judith Villablanca is a Pediatric Hematologist Oncology provider in Los Angeles, California. Dr. Villablanca is rated as a Distinguished provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Retinoblastoma, and Infantile Neutropenia.

VIEW MORE EMBRYONAL TUMOR WITH MULTILAYERED ROSETTES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mascarenhas's expertise for a condition

ConditionClose